HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): David J. Chambers Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Chambers, D. J. Search for Related Content PubMed PubMed Citation Articles by Chambers, D. J. Related Collections Myocardial protection

Ann Thorac Surg 2006;81:1416
© 2006 The Society of Thoracic Surgeons

---

Original article: Cardiovascular

Invited commentary

Cardiac Surgical Research, Cardiothoracic Surgery, The Rayne Institute, Guy’s and St Thomas’ NHS Foundation Trust, St Thomas’ Campus, London, SE1 7EH United Kingdom

(Email: david.chambers@kcl.ac.uk; david.chambers@gstt.nhs.uk).

The first 20% of the full text of this article appears below.

The study by Deja and colleagues [1] is an interesting and important study concerning the potential cardioprotective efficacy of a putative mitochondrial-specific ATP-dependent potassium channel (mK_ATP-channel) opener (diazoxide) in the clinical setting of cardiac surgery. Studies were conducted in isolated right atrial trabeculae obtained from patients undergoing cardiac surgery; the results are controversial as they do not conform to those obtained from a large number of animal-based studies. Essentially these studies demonstrate that optimum protection is seen when diazoxide is present throughout a prolonged period of simulated ischemia (referred to as hypoxia), with protection being enhanced if diazoxide . . . [Full Text of this Article]